Testing version — LOERadar is in active testing. Features and data may change.
EFFEXOR XR (VENLAFAXINE HYDROCHLORIDE) | LOERadar
EFFEXOR XR
NDA
VENLAFAXINE HYDROCHLORIDE | N020699 | UPJOHN US 2 LLC
4 strengths0 unique patents0 unique exclusivities
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
Para IV certification filed but no ANDA patent litigation cases (NOS 835) matched from PACER. Litigation may be pending or filed under a different caption.
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (4)
Sort:
#001 — EQ 37.5MG BASE
RLDAB
0 patents0 exclusivities▴
CAPSULE, EXTENDED RELEASE;ORAL | Approved: Oct 20, 1997
No patent or exclusivity listings for this strength.
#002 — EQ 75MG BASE
RLDAB
0 patents0 exclusivities▾
CAPSULE, EXTENDED RELEASE;ORAL | Approved: Oct 20, 1997
#003 — EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▾
CAPSULE, EXTENDED RELEASE;ORAL | Approved: Oct 20, 1997
#004 — EQ 150MG BASE
RLDAB
0 patents0 exclusivities▾
CAPSULE, EXTENDED RELEASE;ORAL | Approved: Oct 20, 1997